On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the previous day.

On July 9, the company announced it expects first-half revenue of approximately USD 103 million to USD 107 million, representing growth of approximately 272.7% to 287.3% compared to USD 27.5 million in the same period last year. Net profit is expected at USD 33.5 million to USD 39.5 million, a significant turnaround from the net loss of USD 19.2 million recorded in the prior-year period. Adjusted non-IFRS net profit is projected at USD 45.5 million to USD 51.5 million versus an adjusted net loss of USD 15.4 million previously.

The earnings inflection reflects the company's multi-pronged commercial model combining pipeline out-licensing, co-development partnerships, and AI platform services. Recent catalysts include a USD 600 million strategic collaboration with Takeda Pharmaceutical announced on July 2, and the initiation of a Phase 3 clinical trial for its lead AI-discovered drug Rentosertib on July 8.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)